Risperidone Augmentation of Paroxetine in a Case of Severe, Treatment-Refractory Obsessive-Compulsive Disorder Without Comorbid Psychopathology
J Clin Psychiatry 1999;60:55-56 [letter]
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Letter to the Editor
Sir: Risperidone is an atypical antipsychotic drug distinguished from conventional neuroleptics by its antagonism of serotonin receptors of the 5-HT2A and 5-HT7 subtypes while having a similar affinity for dopamine D2 receptors. The novel pharmacologic profile of risperidone suggests the possibility of other therapeutic applications, particularly in disorders putatively associated with abnormal central serotonergic function. Obsessive-compulsive disorder (OCD) is such a disorder, and recent reports suggest that risperidone may be an effective adjunct to treatment of OCD with selective serotonin reuptake inhibitors (SSRIs).